Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction.
Salutary effect of nicorandil, a K+ adenosine triphosphate channel opener, on restoration of myocardial blood flow and functional improvement after coronary revascularization was investigated in 20 patients with first anterior acute myocardial infarction. Ten patients received intracoronary administration of nicorandil (2 mg) after coronary revascularization; the other 10 patients received coronary revascularization only and served as control subjects. Myocardial contrast echocardiography and two-dimensional echocardiography were performed to assess microvascular integrity and regional function in the infarcted area. Nicorandil improved peak contrast intensity ratio (p < 0.001), calculated as the ratio of peak contrast intensity in the infarcted and noninfarcted areas, indicating the restoration of myocardial blood flow to the infarcted myocardium. Regional wall motion improved more significantly in 1 month in patients who received nicorandil (p < 0.01). Thus our results suggested the usefulness of intracoronary nicorandil administration after coronary revascularization for restoring blood flow and functional improvement in patients with acute myocardial infarction.
Sakata
Y
Y
The Cardiovascular Division, Osaka Police Hospital, Kitayama-cho, Tennoji-ku, Japan. sakatah@hp-info.med.osaka-u.ac.jp
Kodama
K
K
Komamura
K
K
Lim
Y J
YJ
Ishikura
F
F
Hirayama
A
A
Kitakaze
M
M
Masuyama
T
T
Hori
M
M
D015906:Angioplasty, Balloon, Coronary; D003287:Contrast Media; D003326:Coronary Circulation / Q000187:drug effects*; D003331:Coronary Vessels; D004452:Echocardiography; D005260:Female; D006801:Humans; D007267:Injections; D007485:Ioxaglic Acid; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D020108:Nicorandil; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015221:Potassium Channels / Q000819:agonists*; D015912:Thrombolytic Therapy
D003287:Contrast Media; D010975:Platelet Aggregation Inhibitors; D015221:Potassium Channels; D009536:Niacinamide; D020108:Nicorandil; D007485:Ioxaglic Acid